All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
EBMT 2018 | Thiotepa-based ASCT is safe and effective in CNS and non-CNS lymphoma
An oral session on lymphoma took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 19 March 2018. Abstract OS1-8 was presented by Herbert G. Sayer, chief doctor at the Helios Hospital Erfurt, Germany on the use of thiotepa-based autologous stem cell transplantation (ASCT) in primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), and non-CNS lymphoma.
Study Overview
- 66 patients were included in the study (median age 59, range 22–78) in this prospective, multi-center, non-interventional trial between October 2013 and April 2017
- Patients with PCNSL (n = 26), SCNSL (n = 12), or non-CNS lymphoma (n = 28) received a thiotepa-containing high-dose chemotherapy (HDC) regimen prior to ASCT
- The HDC regimens were either thiotepa 20 mg/kg, carmustine (BCNU) 400 mg/m2 with or without etoposide 450 mg/m2 (TBE) or thiotepa 10 mg/kg, cytarabine 1600 mg/m2, etoposide 800 mg/m2 and melphalan 140 mg/m2 (TEAM)
- The primary endpoints were toxicity and efficacy
Key Findings
- Most frequent adverse events grade 3-4 included mucositis (60.4%) and infection (45%)
- Five deaths occurred due to therapy-related mortality at Day 100 follow-up; sepsis n = 3, pneumonia n = 1 and multi-organ failure n = 1
- Response at Day 100 follow-up included 59 patients; complete remission n = 52.4%, partial remission n = 42.4% and stable disease n = 5.1%
- Relapse or progression occurred in 21.2% of patients within the first year
- 1-year progression-free survival (PFS)
- PCNSL = 80.1%
- SCNSL = 58.3%
- Non-CNS = 66%
- With regards to the two HDC regimes, there was 73.1% 1-year PFS in patients receiving TBE and 65.7% 1-year PFS in patients receiving TEAM
- 1-year overall survival (OS)
- PCNSL = 84.1%
- SCNSL = 66.7%
- Non-CNS = 70%
- Additionally, there was 78.5% 1-year OS in patients receiving TBE and 73.4% 1-year OS in patients receiving TEAM
Dr. Sayer concluded that these early study results demonstrated promise for thiotepa-based HDC in terms of efficacy for CNS and non-CNS lymphoma with an acceptable safety profile.
References